Hyundai Bioscience announces clinical strategy for dengue fever treatment in US
Predicted impact: Low
US dengue clinical strategy already presented at IDWeek in earlier items.
Hyundai Bioscience현대바이오
048410 · KOSDAQ · ₩048410 · 현대바이오
₩5,370▼ ₩300 (5.29%)End-of-day · Oct 30, 2026 · End-of-day prices.
Hyundai Bioscience presents clinical strategy for antiviral drug 'Jepti' in the US
Predicted impact: Low
Clinical strategy presentation already reported in recent days at the same US conference; no new data.
Zero cure dengue fever? Hyundai Bioscience's 'Jefti' makes global debut at IDWeek in US
Predicted impact: Low
Conference presentation of antiviral trial plan is early-stage and routine.
Hyundai Bioscience Presents Integrated Clinical Trial Plan for Antiviral 'Jepti' at U.S. Infectious Disease Conference
Predicted impact: Medium
Clinical trial plan presented; company revenue is tiny against ₩616B market value, so pipeline news matters
Hyundai Bio Plans Development of SFTS Treatment, Aims for Rapid Entry into Phase 2 Clinical Trial
Predicted impact: Low· Actual: +8.2% vs sector, volume 0.5× normal (5 trading days)
Plan to develop a treatment; early-stage with no size or timeline commitment.
Also known as: Hyundai Bioscience / 현대바이오 / 048410 / KRX:048410
Source: KRX statistical information